Indrayani Biotech board meeting today for approving September quarter result

Thursday, December 11, 2025:Indrayani Biotech Limited has informed BSE Limited that its Board of Directors will meet on Thursday, December 11, 2025, to review key financial and corporate matters. The meeting, earlier postponed due to the Audit Committee’s request for additional information and clarifications, has now been rescheduled.

In a filing under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company stated that the board will consider and approve the Unaudited Financial Results (Standalone and Consolidated) for the quarter and half-year ended September 30, 2025, along with the Limited Review Report from the statutory auditors.

Director Resignation to Be Noted by the Board

The board will also take note of the resignation of Ms. Lakshmiprabha Kasiraman (DIN: 02885912) from her position as Director on the company’s board. Additional business items may also be discussed with the permission of the Chair.

Trading Window to Remain Closed as per Insider Trading Norms

Indrayani Biotech further clarified that, in line with its Code of Conduct for regulating and monitoring insider trading, framed under SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window remains closed for designated persons from October 1, 2025, and will reopen 48 hours after the financial results are made public.

Stock Market Snapshot

As of 2:35 PM IST, the share price of Indrayani Biotech Ltd was at ₹14.30, a 2.22% increase from its previous close of ₹13.94

Source: https://www.bseindia.com/xml-data/corpfiling/AttachHis/be004ef9-74ce-43fd-bf22-baaff05ad314.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations